Using the direct method, create a common-size statement of cash flow for CVS.

A B D 1 C 12 Months Ended Dec. 31, 2018 Dec. 31, 2019 Dec. 31, 2017 5 $248,393,000,000 (149,655,000,000) (52,242,000,000) (28,932,000,000) 955,000,000 (2,954,000,000) (2,717,000,000) 12,848,000,000 po sebi $ 186,519,000,000 (148,981,000,000) (6,897,000,000) (17,234,000,000) 644,000,000 (2,803,000,000) (2,383,000,000) 8,865,000,000 $ 176,594,000,000 (146,469,000,000) (2,810,000,000) (15,348,000,000) 21,000,000 (1,072,000,000) (2,909,000,000) 8,007,000,000 8 7,049,000,000 (7,534,000,000) (2,457,000,000) 5,000,000 817,000,000 (692,000,000) (2,037,000,000) 61,000,000 (137,000,000) (1,918,000,000) Consolidated Statements of Cash Flors - USD ($) 2 3 Cash flows from operating activities: 4 Cash receipts from customers Cash paid for inventory and prescriptions dispensed by retail network pharmacies 6 Insurance benefits paid 7 Cash paid to other suppliers and employees Interest and investment income received 9 Interest paid 10 Income taxes paid 11 Net cash provided by operating activities 12 Cash flows from investing activities: 13 Proceeds from sales and maturities of investments 14 Purchases of investments 15 Purchases of property and equipment 16 Proceeds from sale-leaseback transactions 17 Proceeds from sale-leasebaok transactions 18 Acquisitions (net of cash acquired) 19 Proceeds from sale of subsidiary and other assets 20 Other 21 Net cash used in investing activities 22 Cash flows from financing activities: 23 Net repayments of short-term debt 24 Proceeds from issuance of long-term debt 25 Repayments of long-term debt 26 Derivative settlements 27 Repurchase of common stock 28 Dividends paid 29 Proceeds from exercise of stock options 30 Payments for taxes related to net share settlement of equity awards 31 Other 32 Net cash provided by (used in) financing activities (444,000,000) 0 42,000,000 (3,339,000,000) 0 (42,226,000,000) 832,000,000 21,000,000 (43,285,000,000) 265,000,000 (1,181,000,000) 0 33,000,000 (2,877,000,000) (720,000,000) 3,736,000,000 (8,336,000,000) (25,000,000) 0 (2,603,000,000) 210,000,000 (112,000,000) 0 (7,850,000,000) (556,000,000) 44,343,000,000 (5,522,000,000) 446,000,000 0 (2,038,000,000) 242,000,000 (97,000,000) 1,000,000 36,819,000,000 (598,000,000) 0 0 0 (4,361,000,000) (2,049,000,000) 329,000,000 (71,000,000) (1,000,000) (6,751,000,000) 0 1,659,000,000 4,295,000,000 5,954,000,000 (4,000,000) 2,395,000,000 1,900,000,000 4,295,000,000 1,000,000 (1,620,000,000) 3,520,000,000 1,900,000,000 6,631,000,000 (596,000,000) 6,623,000,000 33 Effect of exchange rate changes on cash, cash equivalents and restricted cash 34 Net increase (decrease) in cash.cash equivalents and restricted cash 35 Cash, cash equivalents and restricted cash at the beginning of the period 36 Cash, cash equivalents and restricted cash at the end of the period 37 Reconciliation of net income (loss) to net cash provided by operating 38 Net income (loss) Adjustments required to reconcile net income (loss) to net cash 39 provided by operating activities: 40 Depreciation and amortization 41 Goodwill impairments 42 Loss on settlement of defined benefit pension plans 43 Stook-based compensation 44 Loss on sale of subsidiary 45 Loss on early extinguishment of debt 46 Deferred income taxes 47 Other noncash items 48 Change in operating assets and liabilities, net of effects from 49 Accounts receivable, net 50 Inventories Other assets 52 Accounts payable and pharmacy claims and discounts payable 53 Health care costs payable and other insurance liabilities 54 Other liabilities 4,371,000,000 0 0 453,000,000 205,000,000 79,000,000 (654,000,000) 264,000,000 2,718,000,000 6,149,000,000 0 280,000,000 86,000,000 0 87,000,000 253,000,000 2,479,000,000 181,000,000 187,000,000 234,000,000 0 0 (1,334,000,000) 53,000,000 51 (2,158,000,000) (1,075,000,000) (614,000,000) 3,550,000,000 320,000,000 $1,476,000,000 (1,139,000,000) (1,153,000,000) (3,000,000) 2,329,000,000 (311,000,000) $ 165,000,000 (941,000,000) (514,000,000) (338,000,000) 1,710,000,000 0 $(333,000,000) A B D 1 C 12 Months Ended Dec. 31, 2018 Dec. 31, 2019 Dec. 31, 2017 5 $248,393,000,000 (149,655,000,000) (52,242,000,000) (28,932,000,000) 955,000,000 (2,954,000,000) (2,717,000,000) 12,848,000,000 po sebi $ 186,519,000,000 (148,981,000,000) (6,897,000,000) (17,234,000,000) 644,000,000 (2,803,000,000) (2,383,000,000) 8,865,000,000 $ 176,594,000,000 (146,469,000,000) (2,810,000,000) (15,348,000,000) 21,000,000 (1,072,000,000) (2,909,000,000) 8,007,000,000 8 7,049,000,000 (7,534,000,000) (2,457,000,000) 5,000,000 817,000,000 (692,000,000) (2,037,000,000) 61,000,000 (137,000,000) (1,918,000,000) Consolidated Statements of Cash Flors - USD ($) 2 3 Cash flows from operating activities: 4 Cash receipts from customers Cash paid for inventory and prescriptions dispensed by retail network pharmacies 6 Insurance benefits paid 7 Cash paid to other suppliers and employees Interest and investment income received 9 Interest paid 10 Income taxes paid 11 Net cash provided by operating activities 12 Cash flows from investing activities: 13 Proceeds from sales and maturities of investments 14 Purchases of investments 15 Purchases of property and equipment 16 Proceeds from sale-leaseback transactions 17 Proceeds from sale-leasebaok transactions 18 Acquisitions (net of cash acquired) 19 Proceeds from sale of subsidiary and other assets 20 Other 21 Net cash used in investing activities 22 Cash flows from financing activities: 23 Net repayments of short-term debt 24 Proceeds from issuance of long-term debt 25 Repayments of long-term debt 26 Derivative settlements 27 Repurchase of common stock 28 Dividends paid 29 Proceeds from exercise of stock options 30 Payments for taxes related to net share settlement of equity awards 31 Other 32 Net cash provided by (used in) financing activities (444,000,000) 0 42,000,000 (3,339,000,000) 0 (42,226,000,000) 832,000,000 21,000,000 (43,285,000,000) 265,000,000 (1,181,000,000) 0 33,000,000 (2,877,000,000) (720,000,000) 3,736,000,000 (8,336,000,000) (25,000,000) 0 (2,603,000,000) 210,000,000 (112,000,000) 0 (7,850,000,000) (556,000,000) 44,343,000,000 (5,522,000,000) 446,000,000 0 (2,038,000,000) 242,000,000 (97,000,000) 1,000,000 36,819,000,000 (598,000,000) 0 0 0 (4,361,000,000) (2,049,000,000) 329,000,000 (71,000,000) (1,000,000) (6,751,000,000) 0 1,659,000,000 4,295,000,000 5,954,000,000 (4,000,000) 2,395,000,000 1,900,000,000 4,295,000,000 1,000,000 (1,620,000,000) 3,520,000,000 1,900,000,000 6,631,000,000 (596,000,000) 6,623,000,000 33 Effect of exchange rate changes on cash, cash equivalents and restricted cash 34 Net increase (decrease) in cash.cash equivalents and restricted cash 35 Cash, cash equivalents and restricted cash at the beginning of the period 36 Cash, cash equivalents and restricted cash at the end of the period 37 Reconciliation of net income (loss) to net cash provided by operating 38 Net income (loss) Adjustments required to reconcile net income (loss) to net cash 39 provided by operating activities: 40 Depreciation and amortization 41 Goodwill impairments 42 Loss on settlement of defined benefit pension plans 43 Stook-based compensation 44 Loss on sale of subsidiary 45 Loss on early extinguishment of debt 46 Deferred income taxes 47 Other noncash items 48 Change in operating assets and liabilities, net of effects from 49 Accounts receivable, net 50 Inventories Other assets 52 Accounts payable and pharmacy claims and discounts payable 53 Health care costs payable and other insurance liabilities 54 Other liabilities 4,371,000,000 0 0 453,000,000 205,000,000 79,000,000 (654,000,000) 264,000,000 2,718,000,000 6,149,000,000 0 280,000,000 86,000,000 0 87,000,000 253,000,000 2,479,000,000 181,000,000 187,000,000 234,000,000 0 0 (1,334,000,000) 53,000,000 51 (2,158,000,000) (1,075,000,000) (614,000,000) 3,550,000,000 320,000,000 $1,476,000,000 (1,139,000,000) (1,153,000,000) (3,000,000) 2,329,000,000 (311,000,000) $ 165,000,000 (941,000,000) (514,000,000) (338,000,000) 1,710,000,000 0 $(333,000,000)